N1VO34 Stock Price and Chart — BMFBOVESPA:N1VO34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk plans to fast-track Wegovy's launch in India to rival Eli Lilly's Mounjaro, which has gained significant attention. Analysts suggest a pricing review for Wegovy may be necessary.

Novo Nordisk alerted consumers about counterfeit Ozempic injections in the U.S. The FDA seized these products on April 9, and Novo Nordisk is testing them for safety.

Novo Nordisk (NOVO_B) experienced a 2.5% increase in trading, contributing to the S&P Europe Select ADR Index's overall rise of 1.19% on Monday.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.